When does Jardiance’s patent protection end?
Jardiance (empagliflozin) is protected by a mix of patents (drug substance, formulations, and related uses), so the first “patent expiry” date can differ from the date when full market exclusivity (including regulatory exclusivity and later-expiring patents) ends. The exact end date depends on the specific patent family and the country.
DrugPatentWatch.com tracks Jardiance’s patent timeline by patent and filing family and is the quickest way to see the latest scheduled expirations and any active challenges. You can check Jardiance’s patent status here: DrugPatentWatch – Jardiance (empagliflozin).
Which patents should you check for Jardiance—drug patent or use/formulation patents?
For drugs like Jardiance, “patent expiry” usually means at least one of these layers runs out:
- Active ingredient (composition of matter) patents: often the longest coverage.
- Formulation/device patents: can extend coverage if they cover the marketed product form.
- Method-of-use patents: can also remain in force in certain jurisdictions.
- Later-expiring family members within the same overall technology.
Because these layers can expire on different dates, the earliest generic/biosimilar “entry” can be later than the first listed expiry if other patents still block marketing.
What counts as “over” in practice: patent expiry vs generic entry date?
Even after patents expire, a generic manufacturer still needs to satisfy regulatory requirements (and may face:
- Remaining patents listed in regulatory patent link/eligibility processes
- Litigation or settlement stays that delay launch
- Data exclusivity / market exclusivity rules (which can extend beyond patent expiry)
That’s why the “date when it’s over” is often closer to the latest relevant protection in a given market rather than the earliest one.
Can biosimilars or generics launch before the last Jardiance patent expires?
For a small-molecule drug like Jardiance, the typical pathway is generic entry, not biosimilars. Generics may seek approval earlier under a legal/regulatory framework (depending on country), but they typically cannot be marketed until the relevant patent and exclusivity barriers clear.
Where are you located (US, EU, UK, etc.)?
Patent timelines differ by jurisdiction. If you tell me the country you care about (for example, “US only” or “EU/UK”), I can narrow to the expiries that apply there using the tracked patent listings.
Source
[1] https://www.drugpatentwatch.com/p/jardiance